Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162519 | 0.98 | TACR1 (0.54) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7250070 | 0.75 | TACR1 (0.54) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4908006 | 0.73 | TACR1 (0.70) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6402093 | 0.72 | TACR1 (0.69) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6074573 | 0.71 | TACR1 (0.44) | TACR1CYP2D6 | |
| SCHEMBL7232238 | 0.71 | TACR1 (0.50) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6228147 | 0.71 | TACR1 (0.50) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6590252 | 0.70 | TACR1 (0.49) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL9007578 | 0.70 | TACR1 (0.52) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6228756 | 0.70 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506775-B1 | Treatment of a gastrointestinal disorder; a central nervous system (CNS) adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans. | PFIZER INC | 2003-01-14 | — | — | US | claimed |